| Trial | Title | Study Record Detail | Phase | Sponsor/Collaborator |
|---|---|---|---|---|
| Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer | NCT01335958 | Phase I | Genentech, Inc./Roche |
Sofituzumab Vedotin is an Anti-MUC15 antibody-drug conjugate also known as RG7458 or DMUC5754A.
Last Editorial Review: August 12, 2015
Your privacy matters to us
We use optional cookies and similar tracking technologies to improve your experience on our website. If you click 'Accept,' you are agreeing to our use and disclosure of your data for those reasons. Click 'Reject' if you do not want us to use and disclose your data for those reasons. If you reject optional cookies, we still use essential cookies for website functionality, and we may de-identify data collected from our website before using it to improve our website experience and see how our website is used. By using our website, you consent to the use of essential cookies.
You may change your preferences, withdraw consent, or obtain more information at any time by clicking 'Preferences.'
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
These cookies are used for managing login functionality on this website.
You can find more information in our Cookie Policy and Privacy Policy.